What Kills Hookworms in Humans: Treatment and Prevention

Albendazole, given as a single 400-mg oral dose, is the most effective first-line drug for killing hookworms in humans, clearing the infection roughly 72% of the time. It works by disrupting the parasite’s ability to absorb glucose, essentially starving the worm to death inside the gut. But treatment is only half the story with hookworm, because reinfection after a successful cure is remarkably common in endemic settings, and the broader picture involves sanitation, footwear, emerging drug resistance, and a vaccine still making its way through clinical trials.

How Hookworms Cause Harm

Understanding what you’re trying to kill helps explain why treatment matters. Hookworms latch onto the lining of the small intestine and feed on blood, and the damage goes beyond the wound itself. The worms secrete anticoagulant substances that keep blood flowing at the attachment site, and the resulting chronic blood loss causes iron-deficiency anemia over time. One species, Ancylostoma duodenale, drains considerably more blood per worm than the other common species, Necator americanus.¹ Even light infections can lead to measurable iron depletion. In children, the anemia from hookworm has been linked to lower cognitive performance, with studies in Cambodian schoolchildren showing that body iron stores declined as hookworm intensity increased.²

Heavy infections can cause outright gastrointestinal bleeding, and the daily iron losses add up quickly. One estimate puts the loss at about 13 mg of iron per day for someone with a moderate worm burden, which is well above what most people absorb from food.³ This is why hookworm is considered one of the most important causes of anemia in the tropics and subtropics, and why treatment needs to be paired with iron supplementation in many cases.

Albendazole and Why It Leads the Pack

Albendazole belongs to the benzimidazole class of drugs. It binds to a structural protein called beta-tubulin inside the worm’s cells, preventing the parasite from maintaining its internal skeleton and absorbing nutrients. A single 400-mg dose achieves a cure rate of about 72% against hookworm, based on a systematic review and meta-analysis that pooled data from hundreds of patients.⁴ That might sound modest for a first-line drug, but the alternatives fare worse.

Mebendazole, another benzimidazole that works through the same general mechanism, managed only about a 15% cure rate against hookworm in that same meta-analysis. Pyrantel pamoate, which paralyzes worms rather than starving them, came in around 31%. The gap between albendazole and its competitors is unusually wide for drugs in the same class, and it explains why global deworming programs rely so heavily on albendazole.⁴ One older trial in an area with mixed parasitic infections found pyrantel pamoate effective against a different nematode but not against hookworm, and levamisole performed poorly against both.⁵

For people who don’t clear the infection with a single dose, a three-day course of albendazole (400 mg daily for three days) is the usual step-up. In practice, clinicians in endemic areas often default to the single dose because it’s simpler to administer in mass treatment campaigns, but individual patients in clinical settings can receive the extended course.

The Drug Resistance Question

When your entire global control strategy rests on one drug, resistance is the nightmare scenario. In veterinary medicine, benzimidazole resistance is already widespread among livestock parasites, driven by specific mutations in the beta-tubulin gene. The question is whether the same thing is happening in human hookworms. Global hookworm control depends on periodic mass drug administration of benzimidazoles to high-risk groups, which creates exactly the kind of selective pressure that breeds resistance.⁶

The evidence so far is a mixed bag. A study from Ghana found resistance-associated mutations at two positions in the hookworm beta-tubulin gene, and those mutations appeared to increase after treatment in people who weren’t cured by albendazole, suggesting that drug exposure may be selecting for resistant worms.⁷ Yet a study from Brazil that screened over 500 individual hookworm eggs from patients across six states found no mutations at one of the key resistance-associated positions.⁸

To complicate things further, researchers who deliberately bred albendazole-resistant hookworms in the lab found that the resistance didn’t come from the usual mutations that cause problems in livestock parasites. None of the known resistance-associated genetic changes were present, meaning the resistance mechanism was something entirely different and not yet characterized.⁹ The practical takeaway: resistance markers are circulating in some hookworm populations, the mechanisms may be more diverse than expected, and continued reliance on a single drug class makes the situation worth watching closely.

Emerging Drug Options

Tribendimidine is the furthest along among new anthelmintic candidates for hookworm. Developed in China and already approved there for other parasites, it has been tested specifically against hookworm in a randomized controlled trial in children. At the 400-mg dose, it reduced egg counts by about 92%, and modeling predicted that a 500-mg dose could push that to roughly 95%.¹⁰ Only mild adverse events were reported. Animal studies have confirmed that tribendimidine and its metabolites have direct activity against Necator americanus.¹¹

Having an alternative with a different mechanism of action matters not just for individual patients who fail albendazole but for the long-term sustainability of global deworming. If benzimidazole resistance does spread, having tribendimidine in the toolbox could be the difference between maintaining control and losing it. That said, tribendimidine is not yet widely registered outside of China for hookworm specifically, so it remains more of a promising backup than a practical option in most countries.

Why Reinfection Happens So Fast

Killing the worms currently inside someone does not prevent new ones from moving in. In endemic areas, people walk on the same contaminated soil, and hookworm larvae are patient. A classic study from Papua New Guinea found that hookworm prevalence returned to pre-treatment levels within two years after chemotherapy, with people acquiring an estimated average of about three new adult worms per year.¹² The study also found that some people were predisposed to heavier reinfection regardless of age or sex, suggesting behavioral or environmental factors that keep certain individuals at persistently high risk.

A study of Ethiopian schoolchildren identified the strongest predictors of reinfection: large household size, poor latrine use, infrequent shoe-wearing, and participation in irrigation work.¹³ Every one of those predictors increases contact between bare skin and contaminated soil, which is the sole route of hookworm transmission for Necator americanus. This is why treatment alone, no matter how effective, cannot eliminate hookworm from a community.

Mass Drug Administration Programs

The public health approach to hookworm relies on treating entire communities at regular intervals, not waiting for individual diagnoses. In Côte d’Ivoire, both annual and semi-annual mass drug administration with ivermectin and albendazole reduced hookworm prevalence dramatically. The annual program cut prevalence from about 24% to 5.5%, while the semi-annual program dropped it from about 12% to under 2%. Moderate and heavy infections were nearly eliminated in both groups. The researchers concluded that annual treatment was an efficient strategy for areas with low to moderate infection rates.¹⁴

A study in Papua New Guinea compared two drug combinations and found an additional benefit: even people who didn’t participate in the treatment saw their hookworm rates drop in communities that received triple-drug therapy (ivermectin, diethylcarbamazine, and albendazole), with prevalence falling by 47% among untreated individuals in those villages.¹⁵ That spillover effect occurs because fewer infected people in the community means fewer hookworm eggs entering the soil, which reduces transmission to everyone. It’s a compelling argument for community-wide treatment rather than treating only confirmed cases.

Prevention on the Ground

Hookworm larvae live in warm, moist soil and infect people by burrowing through the skin, usually the soles of the feet. The single most straightforward prevention measure is wearing shoes. A field trial found sustained reductions in infection intensity for parasites transmitted through the feet when communities received footwear combined with public health messaging.¹⁶ That said, a broader review of hookworm control efforts noted that while footwear campaigns are associated with reduced odds of infection, the evidence for water, sanitation, and hygiene interventions is mixed.¹⁷

The biology of the larvae explains a lot about where prevention works and where it doesn’t. Hookworm eggs need warm temperatures to hatch and develop into infective larvae. Hatching does not occur below 15°C or above 35°C, and the optimal temperature is around 30°C. Larvae are also extremely sensitive to sunlight and drying out. Under bright light, larvae survived a median of only four days, while in the dark they persisted for five to seven weeks depending on the temperature at which they developed.¹⁸ This is why hookworm thrives in warm, shaded, moist environments and why dry, sunny conditions naturally limit transmission. Proper latrine use works as prevention because it keeps feces (and their eggs) out of the soil where people walk barefoot.

Historical data from the American South reinforces the environmental angle. The Rockefeller Sanitary Commission’s campaign against hookworm in the early twentieth century found that environmental conditions like warm temperatures, fine-grained soil, and more frost-free days predicted higher hookworm prevalence, while better sanitation and land improvement were associated with lower rates.¹⁹ That campaign helped dramatically reduce hookworm across the southeastern United States through a combination of treatment and latrine construction, demonstrating that durable control requires addressing the environment, not just the worms already inside people.

Treating Hookworm During Pregnancy

Hookworm is especially damaging during pregnancy because the iron demands are already elevated and anemia carries risks for both the mother and the developing baby. The World Health Organization recommends that pregnant women be included in large-scale deworming programs after the first trimester. The concern is about inadvertent exposure during the first trimester, when organ development is most sensitive, and when a woman may not yet know she is pregnant.²⁰ A systematic review of the evidence found that inadvertent first-trimester exposure did not show clear evidence of harm, but the cautious approach of waiting until the second trimester remains standard guidance. In practice, this means heavily infected pregnant women in endemic areas may go untreated for several months, making iron supplementation all the more important during that window.

Animal Hookworms and Cutaneous Larva Migrans

Not all hookworm infections in humans come from human hookworm species. Dog and cat hookworms (usually Ancylostoma braziliense or Ancylostoma caninum) can penetrate human skin but cannot complete their life cycle in a human host. Instead, the larvae wander aimlessly through the upper layers of skin, creating red, itchy, snake-like tracks. This condition, called cutaneous larva migrans, is one of the most common skin diseases in travelers returning from tropical beaches.²¹

Treatment is straightforward: a single oral dose of ivermectin cures 81–100% of cases, and a single 400-mg dose of albendazole cures 46–100%.²¹ Older treatments like freezing the leading edge of the track or applying topical thiabendazole cream three times daily for two weeks are far less reliable. Misdiagnosis is common, with one estimate suggesting that inappropriate treatment affects 22–58% of travelers with the condition.²² A case from the southeastern United States showed that a patient developed peripheral blood eosinophilia (an uncommon feature) along with the characteristic migratory rash, and a single dose of ivermectin resolved the symptoms within three days.²³ You can pick up animal hookworm larvae from contaminated sand or soil anywhere warm and humid, not just in the tropics.

Diagnosing Hookworm and Confirming a Cure

Hookworm is traditionally diagnosed by examining stool samples under a microscope using the Kato-Katz technique, which involves counting eggs. It’s cheap and practical for field use, but it misses a lot of infections, especially light ones. When compared head-to-head with molecular testing (real-time PCR), Kato-Katz detected only about 43% of hookworm-positive samples that PCR identified at follow-up after treatment.²⁴ Another study found roughly 30% discordance between the two methods for hookworm, with PCR picking up the vast majority of cases that Kato-Katz missed.²⁵

This matters for confirming a cure. If you’re relying on a microscopy method that misses more than half of remaining infections, you’ll overestimate how well a treatment worked. Studies that use PCR to measure drug efficacy tend to report lower cure rates than those using microscopy alone. For clinical trials testing new drugs, this distinction is increasingly important. For individual patients in non-endemic countries, PCR-based stool tests are more widely available through reference laboratories and are the more reliable way to verify that treatment worked.

Where the Hookworm Vaccine Stands

A human hookworm vaccine has been in development for over a decade through the Sabin Vaccine Institute. The candidate vaccine targets two enzymes the parasite needs to feed on blood: Na-GST-1, which helps the worm detoxify hemoglobin breakdown products, and Na-APR-1, a protease that helps digest the blood meal.²⁶ The idea isn’t necessarily to prevent infection entirely but to reduce worm burden and blood loss enough to prevent the anemia and developmental harm that make hookworm so damaging.

A phase 1 trial of the Na-APR-1 component in hookworm-naive adults found it was well tolerated and triggered strong antibody responses, and trials subsequently moved into endemic areas of Gabon and Brazil.²⁷ Progress has been slow compared to vaccines for viral diseases, in part because developing a vaccine against a multicellular parasite is fundamentally harder than targeting a virus or bacterium. Parasites have complex life cycles with multiple stages, each presenting different antigens, and hookworms in particular actively suppress the host immune system. During infection, the worms shift the immune response toward regulatory pathways that dampen inflammation, including increased activity of regulatory T cells and suppression of certain pro-inflammatory signals.²⁸ A vaccine has to overcome a parasite that has evolved sophisticated tools for making the immune system tolerant of its presence.

Hookworms as Therapy for Autoimmune Disease

The immunosuppressive abilities of hookworms have inspired an unusual line of research: deliberately infecting people with a controlled number of hookworm larvae to dampen overactive immune responses in autoimmune diseases. The logic follows from observations that hookworm infection suppresses inflammatory pathways and promotes regulatory immune activity, including elevated levels of the anti-inflammatory signaling molecule IL-10 and suppression of the Th17 pathway associated with autoimmune inflammation.²⁸

One of the most rigorous tests of this idea was a randomized, placebo-controlled trial involving 54 people with celiac disease. Participants received either 20 or 40 hookworm larvae or a placebo, then gradually escalated their gluten consumption over more than a year. The results were mixed: hookworm infection did not restore tolerance to sustained moderate gluten consumption (2 grams per day), but participants infected with hookworms reported improved symptom scores during a phase of lower, intermittent gluten exposure. Participants who received hookworms also experienced fewer adverse events overall than the placebo group.²⁹ The therapeutic hookworm concept remains experimental and has not produced a breakthrough result in any autoimmune condition so far, but it reflects a broader scientific interest in understanding how parasites modulate human immunity rather than simply treating them as threats to be eliminated.